Najla El Jurdi, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10 Room 8D44C
- Bethesda, MD 20892
- 240-858-7096
- najla.eljurdi@nih.gov
RESEARCH SUMMARY
Dr. El Jurdi is a hematopoietic cell transplantation and cellular therapy physician focused on clinical and translational investigations to better understand, prevent, and treat Graft-versus-Host Disease (GVHD), with a particular emphasis on chronic GVHD. Her goal is to leverage the expertise of the NIH GVHD multidisciplinary team and intramural program to bring forth novel clinical trials and therapeutic approaches for GVHD. She is strongly committed to improving toxicities, preventing late effects, and improving quality of life for hematopoietic cell transplant patients and survivors.
Areas of Expertise
Najla El Jurdi, M.D.
Research
Dr. El Jurdi’s research focuses on clinical and translational investigations aimed at advancing the understanding, prediction, prevention, and treatment of GVHD, with a particular emphasis on chronic GVHD. Dr. El Jurdi incorporates multidisciplinary and interdisciplinary collaborations with peers in immunology, genomics, microbiology, bioinformatics, and other disciplines to address critical questions and areas of need in GVHD prevention and treatment. Dr. El Jurdi focuses on developing novel therapeutic approaches for highly morbid forms of chronic GVHD. She is equally strongly committed to research aimed at understanding accelerated aging after transplantation, improving toxicities, preventing late effects, and improving quality of life for transplant patients and survivors.
Biography
Najla El Jurdi, M.D.
Dr. El Jurdi was awarded her M.D. degree with distinction in 2011 from the American University of Beirut. She subsequently completed internal medicine training at Tufts Medical Center and fellowship training in hematology, oncology and transplantation at Case Western Reserve University, during which she also served as Chief Fellow. During fellowship she conducted studies in the lab investigating the role of oral and fecal microbiome in the development of post-transplant toxicities. In 2018, she joined the Transplantation and Cell Therapy faculty at University of Minnesota as an Assistant Professor of Medicine on the academic track with research focus. Dr. El Jurdi completed the AACR/ASCO Clinical Cancer Research Scholar Course (2016) and AAMC Early Career Women Faculty Leadership Development Excellence Program (2022). She is a member of multiple societies including Alpha Omega Alpha (AOA) Honor Medical Society (2011), American Society of Hematology, American Society of Transplantation and Cellular Therapy, Center for International Blood and Marrow Transplant Research, The Blood and Marrow Transplant Clinical Trials Network, European Society of Blood and Marrow Transplantation, and the Chronic GVHD Consortium. Dr. El Jurdi is board certified in General Internal Medicine, Hematology, and Oncology.